# Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

> **NCT01420549** · PHASE3 · COMPLETED · sponsor: **Ache Laboratorios Farmaceuticos S.A.** · enrollment: 129 (actual)

## Conditions studied

- Hypercholesterolemia
- Dyslipidemia

## Interventions

- **DRUG:** Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
- **DRUG:** Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

## Key facts

- **NCT ID:** NCT01420549
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420549, "Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01420549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*